# Safety of REL-1017 for Major Depressive Disorder

> **NCT04855760** · PHASE3 · COMPLETED · sponsor: **Relmada Therapeutics, Inc.** · enrollment: 627 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** REL-1017

## Key facts

- **NCT ID:** NCT04855760
- **Lead sponsor:** Relmada Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2023-07-27
- **Final completion:** 2023-07-27
- **Target enrollment:** 627 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855760, "Safety of REL-1017 for Major Depressive Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04855760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*